Lu Zhang

A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma

Zhenyu Li, Qingyuan Zhang, J. Zhou, 2022, Leukemia & lymphoma.

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.

Yan Yuan, Yan Ma, Xiao-ping Xu, 2017, Oncotarget.

A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas

F. Cavalli, L. Mazzucchelli, A. Stathis, 2021, Leukemia & lymphoma.

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

L. Cascione, D. Rossi, A. Stathis, 2019, Haematologica.

Excipient-free prodrug-based three-in-one nanoparticles co-deliver diversified agents to amplify tumor therapy

Zhenzhen Yang, Xianrong Qi, Yanxia Zhou, 2022, Chemical Engineering Journal.

with other anti-lymphoma targeted agents The BTK inhibitor zanubrutinib ( BGB-3111 ) demonstrated synergies Version 2 HAEMATOL / 2018 / 214759 Haematologica Bertoni

L. Cascione, D. Rossi, A. Stathis, 2019 .